Stockscreener 앱 받기
25.78
0.12%
0.03
시간 외 거래:
25.78
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com
Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart
100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia
Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo
Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com
CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options - Stock Titan
Maze Therapeutics, Inc. (MAZE) reports Q1 loss, beats revenue estimates - MSN
HighVista Strategies Sells Maze Therapeutics Shares in Q1 2026News and Statistics - IndexBox
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge - Intellectia AI
JP Morgan Maintains Maze Therapeutics (MAZE) Overweight Recommendation - MSN
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts - Yahoo Finance
Wall Street Zen Upgrades Maze Therapeutics (NASDAQ:MAZE) to Hold - MarketBeat
Rule 144 notice: MAZE (NASDAQ: MAZE) lists Common share lots and broker - Stock Titan
Janus Henderson (MAZE) discloses 2.86M shares, a 5.8% stake - Stock Titan
Maze Therapeutics stock falls despite strong phase 2 kidney drug data for MZE829 - MSN
MAZE Stock Price, Quote & Chart | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110 - Moomoo
[EFFECT] Maze Therapeutics, Inc. SEC Filing - Stock Titan
Maze Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline - TipRanks
LifeSci Capital Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Maze Therapeutics 1Q License Rev $20M >MAZE - Moomoo
Maze Therapeutics Expects Will Fund Ops Into 2029 Based on Its Current Business Plan >MAZE - Moomoo
Maze Therapeutics Inc. unveils quarterly results and updates on operational advances - Traders Union
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Maze Therapeutics 1Q Loss/Shr 45c >MAZE - Moomoo
Maze Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.45) — 10-Q Summary - TradingView
Maze Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Maze Therapeutics (NASDAQ: MAZE) trims Q1 loss as cash, pipeline and Shionogi milestone grow - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) Q1 2026 loss narrows on milestone revenue - Stock Titan
[POS AM] Maze Therapeutics, Inc. SEC Filing - Stock Titan
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights - The Manila Times
What date does Maze Therapeutics, Inc.'s (MAZE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness - Yahoo Finance
TradingKey - TradingKey
Number of shareholders of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Assessing Maze Therapeutics (MAZE) Valuation After Mixed Returns And A Premium Price To Book Multiple - Sahm
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Exploring a Potential 149.49% Upside in Biotech - DirectorsTalk Interviews
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials - The Motley Fool
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials - The Motley Fool
Maze Therapeutics (MAZE) CSBO exercises options for 14,305 shares - Stock Titan
Director Charles Homcy gifts 7,422 Maze Therapeutics (MAZE) shares - Stock Titan
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock - MarketBeat
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN
Maze Therapeutics (NASDAQ: MAZE) details 2026 proxy, board slate and executive pay - Stock Titan
2.98%
1.33%
자본화:
|
볼륨(24시간):